Intra-Cellular Therapies (ITCI) Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression Met the Primary Endpoint
Go back to Intra-Cellular Therapies (ITCI) Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression Met the Primary Endpoint| INTRA-CELL THRP (NASDAQ: ITCI) | Delayed: 72.13 -0.99 (1.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $73.12 | 52 Week High | $59.96 | |||
| Open | $72.46 | 52 Week Low | $10.80 | |||
| Day High | $72.78 | P/E | N/A | |||
| Day Low | $71.35 | EPS | $0.00 | |||
| Volume | 658,777 | |||||
